Effective July 1, the Hahn-Schickard Association for Applied Research e.V. will spin off its operational business and transfer it to the newly founded Hahn-Schickard gGmbH. This nonprofit company has assumed the universal legal succession of the association and has been entered in the commercial register of the Stuttgart District Court. It is legally represented by its managing director, Dr. Karl-Peter Fritz.

FlareOn Biotech - fluorescence-guided tumour margin detection - 01/07/2026

A sensor designed to visualise residual tumour tissue during surgery

In order to safely remove tumours in the head and neck region, surgeons must be able to reliably distinguish diseased tissue from healthy tissue. FlareOn Biotech, a start-up based in Frickenhausen, has developed a biochemical sensor capable of visualising tumour cells in tissue samples directly in the operating theatre within just ten minutes. The company is now seeking partners to help bring its diagnostic platform to market.

For his research on the development of rare malignant tumors in the hereditary DICER1 tumor predisposition syndrome, Dr. Felix Kommoss has been awarded the Rudolf Virchow Prize of the German Society of Pathology. Dr. Kommoss conducts research at the Heidelberg Faculty of Medicine at Heidelberg University and serves as Senior Physician and Head of Gynecologic Pathology at the Institute of Pathology, Heidelberg University Hospital.

Gelatin is a versatile natural material. To tailor its properties specifically to the various applications in medicine, diagnostics, and cosmetics, the Fraunhofer IGB has developed a toolbox for chemical functionalization. With the help of automated processes, the modifications can now be scaled under defined conditions, and reproducible batches of modified gelatin can be produced on a scale ranging from grams to kg for customer sampling.

The Collaborative Research Center (SFB) “High Performance Compact Magnetic Resonance” (HyPERiON) has been exploring new avenues in magnetic resonance technology since 2022. Under the leadership of the Karlsruhe Institute of Technology (KIT), the researchers aim to develop high-performance magnetic resonance systems in a benchtop format to make them suitable for widespread use.

Experts in Heidelberg have developed an AI system that can classify brain tumors with unprecedented accuracy using standard microscopic tissue sections. Using digitized standard stains, the system identifies more than 100 molecular subtypes of central nervous system tumors, delivers results within minutes, and could accelerate the diagnosis of brain tumors worldwide.

In response to stress or damage, cells undergo senescence and stop dividing. However, if senescent cells accumulate in tissues over the long term, chronic inflammation occurs and the risk of cancer increases. Researchers at the German Cancer Research Center (DKFZ) have now discovered a previously unknown mechanism by which senescent cells protect themselves from oxidative stress and a specific form of cell death known as ferroptosis.

Quantum sensors for magnetic measurements - 02/06/2026

New insights into muscle physiology – contactless and three-dimensional

Contactless measurement of muscle activity and training effects: using highly sensitive quantum sensors, researchers at the Universities of Tübingen and Stuttgart are setting new standards. This technology has the potential to revolutionise clinical diagnostics and optimise training and neuroscience research.

Joint press release of the Heidelberg Faculty of Medicine at Heidelberg University and the German Center for Infection Research: With the FDA approval of Hepcludex (bulevirtide), a therapy for chronic hepatitis D developed at the Heidelberg Faculty of Medicine at Heidelberg University, Heidelberg University Hospital, and the German Center for Infection Research (DZIF) has now reached the world’s most important pharmaceutical market.

Chronic pain is among the most common and burdensome health conditions worldwide. But which processes in the nervous system cause pain to be “learned” and thus persist long term? And how can insights into the mechanisms underlying chronic pain be translated into new therapeutic approaches? These questions have been at the core of Rohini Kuner’s research for many years.

Medical Center – University of Freiburg demonstrates a fundamental therapeutic approach for hereditary immune system defects in a mouse model. The safety profile of genome editing varies significantly depending on the method and cell type.

The Medical Center – University of Freiburg has been certified for the first time as a “Center of Excellence” by the European Neuroendocrine Tumor Society (ENETS). The professional association recognizes specialized centers that treat rare tumor diseases in accordance with established quality standards. Neuroendocrine tumors are rare cancers that can arise from hormone-producing cells.

AI is transforming science and does not stop at neuroscience. In this interview, we speak to Gabriele Lohmann about her research at the intersection of the brain and algorithms. She talks about the use of artificial intelligence as a research tool, the decoding of brain activity, and why large language models do not understand what they are doing.

NVision announced a $55 million Series B led by Abbott and unveiled PIQC, a new quantum computing platform built on its molecular quantum technology.

High blood pressure is one of the most common causes of heart attacks, strokes, kidney damage, and vascular diseases. Many people affected experience no symptoms for a long time. This is precisely why it is important to check your blood pressure regularly. To mark World Hypertension Day on May 17, the Medical Center – University of Freiburg is providing information on warning signs, diagnosis, and treatment options.

Prof. Dr Simon Elsässer will be awarded one of this year’s Alexander von Humboldt Professorships in Berlin on 12 May 2026. With funding of five million euros, Elsässer will strengthen Freiburg’s research focus ‘Signals of Life’ over the next five years. In this interview, he discusses complex decision-making processes in cells, the significance of signals and what makes the research environment in Freiburg so special.

The ability of cancer cells to change their identity makes tumors such as glioblastoma particularly aggressive and resistant to treatment. Moritz Mall, of the German Cancer Research Center (DKFZ) and the Hector Institute for Translational Brain Research (HITBR), is investigating how this plasticity can be specifically restricted. His approach focuses on genetic “guardians” that suppress alternative cell programs.

The Athletin-D project combines the universities of Bochum, Freiburg, Wuppertal and the Technical University of Munich on research into how the performance and health of female athletes could be improved in Olympic and paralympic sports. At the University of Freiburg, the sports psychologist Professor Jana Strahler is studying the interaction of hormonal processes, stress, lifestyle factors and mental health.

Scientists from the German Cancer Research Center (DKFZ) and the HI-STEM* Stem Cell Institute have deciphered a key mechanism that contributes to treatment failure in acute myeloid leukemia (AML). They show that there are not just one, but four different subtypes of leukemia stem cells. This diversity could explain why one of the most important AML drugs does not work sufficiently in some patients or loses its effectiveness over time.

MRI analysis of fat and muscle distribution in more than 66,000 people provides a more accurate assessment of health risks / Poor muscle quality poses an additional risk / Study provides reference values based on age, sex, and height

Led by researchers from Heidelberg Faculty of Medicine at Heidelberg University and the University of California, San Francisco (USA), an international research team has evaluated a novel approach for the diagnosis of pulmonary tuberculosis. The method enables detection of Mycobacterium tuberculosis without laboratory infrastructure, within a markedly shorter time frame than conventional diagnostics, and using a simple swab.

The University of Freiburg works closely with partners from various sectors including academia, business, politics and public administration through the Innovation Alliance Foundation Freiburg. The resolution that has been adopted reinforces the shared goal of establishing Freiburg as an attractive innovation hub with international appeal.

Prof. Dr. Halbritter has served as the new Medical Director of the Department of Nephrology at the Medical Center – University of Freiburg since April 2026. With his expertise, he is enhancing care for patients with kidney disease: The goal is to prevent kidney failure through early diagnosis and the implementation of strategies to slow disease progression. For cases where kidney failure has already occurred, the focus is on organ replacement.

Not only actual chronological age, but also individual aging at the molecular level is a key factor in the development of cancer. This was discovered by scientists at the DKFZ and the Saarland Cancer Registry. If the so-called “epigenetic clocks” indicate accelerated biological aging, the likelihood of a cancer diagnosis increases. This finding could help identify at-risk groups and make early detection screenings more targeted

A recent study published in the European Respiratory Journal provides important new insights into the early identification and monitoring of chronic obstructive pulmonary disease (COPD). The focus is on airway wall thickness as an imaging marker for structural remodeling processes in the lungs.

Desmoplastic small- and round-cell tumor is rare, aggressive, and difficult to treat. Researchers at the National Center for Tumor Diseases (NCT) Heidelberg and the German Cancer Research Center (DKFZ) have comprehensively analyzed 30 tumors and identified potential personalized treatment options for nearly all patients. In some patients, new targeted approaches were able to halt the disease for a surprisingly long time.

Photoimmunotherapy - 09/04/2026

Switching off tumours with light: how photons can be used to target prostate cancer

Prostate cancer is the most common cancer among men in Germany. Relapses and the harsh side effects of traditional treatments remain a major challenge, even with advanced surgical techniques. At the University of Freiburg, Dr. Wolf is pioneering the development of photoimmunotherapy. Photoimmunotherapy combines light, antibodies and a specialised dye to precisely target tumour cells - simultaneously 'waking up' the immune system.

How does sugar affect relaxation exercises? A new study carried out by researchers from the University of Konstanz provides revealing insights into the connection between blood glucose and the autonomic nervous system: The intake of sugar counteracts relaxation.

The Volkswagen Foundation is supporting the Ulm scientist Professor Walter Karlen with more than 940,000 euros from the funding initiative "Momentum - funding for first-time researchers". The engineer has headed the Institute of Biomedical Engineering at Ulm University since 2021. Karlen conducts research in the field of mobile health on so-called Medicine Wearables, i.e. portable technology for recording health data.

Women who have experienced a stroke or heart attack are at a higher risk of mortality than men. Fraunhofer researchers want to improve gender-specific aftercare with a customized assistance system – thus helping to prevent further heart disease.

Creating scope for innovative projects from various disciplines: That is the aim of the research incubators at Ulm University. The aim is to initiate developments and ideas that could become relevant research areas for the University. In the current call for proposals, the jury has selected two interdisciplinary projects on quantum chemistry and digital, sensor-based diabetes research.

Proof-of-concept study of organoid technology - 26/03/2026

Can organoids improve the treatment of pancreatic cancer?

A clinical trial called UNITEPANC is exploring whether organoid-based approaches can improve the treatment of pancreatic cancer. BIOPRO Baden-Württemberg spoke with the study’s principal investigator and pancreatic cancer specialist, Prof. Dr. Thomas Seufferlein of University Hospital Ulm, to discuss the disease more broadly along with the specific aims of the trial. The interview was conducted by Walter Pytlik on behalf of BIOPRO.

For the first time, researchers have succeeded in mapping the organization of immune cells in human lymph nodes. The study was led by scientists from Heinrich Heine University Düsseldorf, Düsseldorf University Hospital, the DKFZ, the European Molecular Biology Laboratory (EMBL), and the Max Delbrück Center (MDC) in Berlin. They were able to demonstrate why the architecture of healthy lymph nodes is altered in malignant lymphomas.

In ovarian cancer, immunotherapies using checkpoint inhibitors have so far been effective in only a small number of patients. Researchers at the HI-TRON Mainz* have now discovered that lipid metabolism processes in the tumor microenvironment play a decisive role in how well such therapies work. The findings open up new avenues for using immunotherapies in a more targeted manner, increasing their effectiveness, and overcoming resistance.

How can artificial intelligence support medical imaging diagnostics in the future and significantly improve patient care? Researchers led by Lena Maier-Hein (German Cancer Research Center, DKFZ, and NCT Heidelberg) have developed an innovative concept to address this question. The Carl Zeiss-Stiftung is funding the MEDAL* project with a total of three million euros.

The Dr. Margarete Fischer-Bosch Institute for Clinical Pharmacology (IKP) at the Bosch Health Campus in Stuttgart is leading Europe’s first EU project to systematically integrate pharmacogenomics into molecular tumor boards (MTB). The goal of PGxMTB is to systematically incorporate patients’ genetic factors into treatment decisions, thereby making cancer therapies safer and more effective.

Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) belong to a spectrum of neurodegenerative diseases with overlapping symptoms. Many patients have a common hallmark: A protein called TDP-43 clumps together in the neurons of the brain to form tiny lumps. Researchers at DZNE and Ulm University Hospital, together with international experts, have now discovered that these pathological changes primarily affect certain cells.

A certain blood protein regarded as an early indicator of Alzheimer’s disease also appears to play a role in other disorders. Researchers at DZNE and the Hertie Institute for Clinical Brain Research (HIH) at the University of Tübingen have found that elevated levels of phosphorylated tau protein (pTau) also occur in two lesser-known conditions that primarily affect the heart and kidneys.

Immunotherapies have greatly improved the treatment of metastatic melanoma, but they can cause serious side effects. A study led by researchers from Heidelberg University's Medical Faculty, the Heidelberg University Hospital, and the NCT in Heidelberg now shows that autoantibodies detected in the blood before the start of therapy could help to better assess the individual risk of side effects in patients.

The introduction of mammography screening programs in Europe has significantly changed breast cancer diagnoses, accompanied by a decline in breast cancer mortality rates. This is shown by the most comprehensive analyses of population-based data on breast cancer in 21 European countries to date, led by the DKFZ. The most striking finding: after the introduction of screening, significantly more early-stage, less advanced tumors were detected.

An international team led by Professor Tobias M. Böckers from Ulm University Medical Centre has been awarded up to 1.7 million euros to develop a novel therapy for a rare, syndromic form of autism. The research project focuses on a gene whose loss of function can manifest itself in severe impairments in language, behaviour and everyday functions of those affected.

Technology impulse for the Lake Constance region: The new Single Cell Centre at the University of Konstanz offers technology and expertise to study cells individually and at high resolution – for applications in medical diagnostics, medication development and basic research at universities.

Chemotherapy is often a central component of treatment for advanced colorectal cancer. However, not every therapy is equally effective for every patient. Researchers from the German Cancer Research Center (DKFZ), the HI-STEM* stem cell institute, and the biotech company Xilis in Utrecht, Netherlands, have now developed a new method for selecting the most effective drug before treatment begins.

New findings indicate that a shingles vaccination could not only reduce the risk of cognitive impairment and dementia, but also reduce disease progression among those living with dementia.

In a published scientific study, researchers have succeeded in accurately diagnosing common types of brain tumors in children and adolescents based on tumor-derived genetic material in cerebrospinal fluid. Until now, these so-called liquid biopsies were not capable enough for such reliable diagnostics. The international research team has therefore optimized a sequencing technique and developed an AI-based computational method. In a later step,…

nanodiag BW has received approval from the BMFTR for a further three-year implementation phase under the Clusters4Future initiative. With the approval of €15 million, the innovation network will be able to continue its work on nanopore-based diagnostic methods seamlessly from April 2026 onwards. The Baden-Württemberg Ministry of Economic Affairs, Labour and Tourism is supporting the cluster management through accompanying measures.

Scientists at the German Cancer Research Center (DKFZ), Heidelberg University Hospital (UKHD), and Mannheim University Medical Center (UMM) are presenting a method that enables artificial intelligence (AI) to learn how to transfer medical image data from animals to humans. This “xeno-learning” could help make surgical procedures safer and more precise in the future – without relying on human training data.

Researchers at the National Center for Tumor Diseases (NCT) Heidelberg and the German Cancer Research Center (DKFZ) have developed a digital tool that significantly accelerates and improves clinical decisions in molecular precision oncology. The Knowledge Connector enables the structured and standardized evaluation of very extensive molecular tumor profiles and makes them available for personalized therapy decisions faster than before.

Recreating tumour tissue in the laboratory as realistically as possible and developing new approaches for personalised cancer medicine: A total of 20 doctoral students in the life sciences and ten Medicine students will be researching this in the new "Organoid-Based mOdelling of Solid Tumours" research training group. They want to gain a better understanding of cancer and better predict the course of the disease and the effect of…

The European Commission has today proposed an ambitious package of measures to improve the health of EU citizens, while ensuring the long-term resilience and competitiveness of the health sector.